Effect of IV ferric carboxymaltose treatment on platelet counts and serum transferrin levels in CKD patients not on dialysis with iron deficiency: potential implications for thrombogenicity

Read full text Summarise with VIRAT
Authors: Aleix Cases, María Jesús Puchades, Juan Casas Todolí, Julio Nuñez, Carlos J. Peña, José Luis Górriz
Cited by: 0
References: 31

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Anemia and iron deficiency (ID) are common complications in chronic kidney disease (CKD). Beyond their haematological impact, ID has been linked to heightened thrombotic risk, partly through increases in platelet counts and circulating transferrin. We investigated whether correction of ID with intravenous ferric carboxymaltose (FCM) could modify these parameters in CKD patients with mild anemia. This prospective single-centre study included 41 patients with non-dialysis CKD (mean age 74.9 ± 9.5 years, 66% male), mild anemia, and ID. All received IV FCM (mean dose 616.2 ± 163.8 mg) and were analyzed at baseline and after 4 weeks. Hemoglobin (Hb) levels increased non-significantly (10.9 ± 0.4 vs. 11.1 ± 0.4 g/dL, p = NS). In contrast, platelet counts (240 ± 86 × 109/L vs 222 ± 63 × 109/L, p < 0.001) and serum transferrin levels (265 [235–314] vs. 217 [191–237] mg/dL, p < 0.001) declined significantly. Baseline platelet counts and serum transferrin levels were associated with serum ferritin (r = −0.332, p = 0.04 and r = −0.629, p = 0.001, respectively) and TSAT (r = −0.40, p = 0.01 and r = −0.671, p = 0.001, respectively), but not with Hb levels. ID correction with IV FCM was associated with significant reductions in platelet counts and serum transferrin levels. These findings suggest a link between iron repletion and modulation of thrombogenic pathways in a population at high risk of atherothrombotic events, but warrant confirmation in prospective controlled studies.

Fields of Study & Subjects

Iron Metabolism and Disorders Erythropoietin and Anemia Treatment Blood transfusion and management

Publication details

Journal / source
Renal Failure
Volume
48
Issue
1
Pages
2644786–2644786
Publication date
30 March 2026
Language
EN